PATIENTS with immune-mediated inflammatory diseases who are being treated with Janus kinase (JAK) inhibitors may be at an increased risk of herpes zoster infection, according to results of a study published in Frontiers in Pharmacology.
"The mechanism underlying the association between JAK inhibitor therapy and increased risk of herpes zoster infection is not entirely clear," the authors wrote.
"The inhibition of JAK signalling may impair the immune system's ability to make antiviral cytokines which may be a contributing factor."
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Oct 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Oct 23
